Novo Nordisk A/S (LON:0TDD)

London · Delayed Price · Currency is GBP · Price in USD

48.18

+0.14 (0.29%)

At close: Dec 5, 2025

-56.37% (1Y)

Market Cap	160.83B
Revenue (ttm)	36.88B
Net Income (ttm)	12.13B
Shares Out	n/a
EPS (ttm)	2.73
PE Ratio	13.26
Forward PE	12.51
Dividend	0.94 (1.95%)
Ex-Dividend Date	Aug 18, 2025

Volume	68,990
Average Volume	245,062
Open	48.04
Previous Close	48.04
Day's Range	47.94 - 49.13
52-Week Range	41.45 - 112.50
Beta	n/a
RSI	45.41
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Industry Pharmaceutical Preparations

Founded 1923

Employees 77,349

Stock Exchange London Stock Exchange

Ticker Symbol 0TDD

Full Company Profile

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK Financial Statements

News

There is no news available yet.